Prima BioMed Ltd, a biotechnology company, engages in the research and commercialization of licensed medical biotechnology products in Australia. It develops oncology therapies in the field of immunotherapy. The companys lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. It also manufactures mannosylated fusion protein, a critical component to CVac that contains the antigen necessary for the dendritic cells to illicit an immune response against tumor cells. In addition, the company focuses on developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd is based in Sydney, Australia.